Lead Product(s) : EDV,Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : ImmunityBio
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the deal, EnGeneIC will grant ImmunityBio an exclusive, worldwide licence to develop, manufacture and commercialize EDV™ in combination with its anti-cancer drugs and COVID-19 vaccine.
Product Name : EDV
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
November 30, 2021
Lead Product(s) : EDV,Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : ImmunityBio
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Remestemcel-L
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Mesoblast To Evaluate Anti-Inflammatory Cell Therapy Remestemcel-L
Details : A clinical study conducted in China reported that allogeneic MSCs cured or significantly improved functional outcomes in all seven treated patients with severe COVID-19 pneumonia.
Product Name : Ryoncil
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 03, 2020
Lead Product(s) : Remestemcel-L
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Astodrimer Sodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Starpharma Provides Development Update on Spl7013 Nasal Spray for Covid-19
Details : Based on discussions with regulators, the company expects to be able to expedite approval of a SPL7013 nasal spray by leveraging existing nonclinical and clinical data of Starpharma’s currently approved and marketed products.
Product Name : Viraleze
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 25, 2020
Lead Product(s) : Astodrimer Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cinnamoylguanidine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biotron’s Compound BIT036 as an antiviral for COVID-19
Details : Biotron was first to demonstrate that the E Protein within SARS is a viroporin, and has since developed compounds that inhibit viroporin activity.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 03, 2020
Lead Product(s) : Cinnamoylguanidine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Panaphix
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Novotech Wins Cro Contract For Komipharm Coronavirus Covid-19 Clinical Trial In South Korea
Details : The company said it seeks to expand the use of Panaphix to cover COVID-19 treatment through this proposed clinical trial.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 03, 2020
Lead Product(s) : Panaphix
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IC14
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The trial will assess if IC14 can temper the immune system’s response to coronavirus infection of the lungs, thus preventing dangerous levels of inflammation.
Product Name : IC14
Product Type : Antibody
Upfront Cash : Inapplicable
April 29, 2020
Lead Product(s) : IC14
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Propagermanium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Global Remap-Cap Platform Trial Protocol to Include Dmx-200 in Covid-19 Patients
Details : DMX-200 has been selected for inclusion in the protocol as a new treatment arm in the global the REMAP-CAP program aimed at treating patients with Acute Respiratory Distress Syndrome (ARDS) as a result of COVID-19.
Product Name : DMX-200
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 06, 2020
Lead Product(s) : Propagermanium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable